No Data
No Data
China Securities Co., Ltd. expects that the "expanding domestic demand" trade will gradually grow, covering cyclical and growth stocks.
China Securities Co.,Ltd. released a research report stating that it is expected that the 'expanding domestic demand' trade will gradually grow, covering both cyclical and growth stocks.
Nomura Adjusts Hangzhou Tigermed Consulting's Price Target to HK$30.65 From HK$32.69, Keeps at Neutral
Tigermed (03347): Fangda Shanghai intends to provide guarantee for Fanglin Pharmaceutical.
Tigermed (03347) announced that the company's holding subsidiary, Shanghai FangLing Pharmaceutical Technology Co., Ltd. (hereinafter referred to as...
Statistics on the proportion of mainland investors in the SmartHK Stock Connect program | July 23rd
Statistics of unusual proportion of Wise H.K. Connect | July 22, 2024.
Tigermed (03347.HK) spent 2.7083 million yuan to repurchase 0.05 million A shares on July 22.
On July 22, Gelunhui reported that Tigermed (03347.HK) will purchase 0.05 million A-shares, at a cost of 2.7083 million yuan, on July 22, 2024. The repurchase price is between 54.14 and 54.25 yuan per share.
Contract research organizations are generally increasing. Pharmaron (03759) rose 6.66%, and Orient Securities is expected to see marginal improvement in the sector.
Jingu Financial News| The concept of contract research organizations is rising across the board. As of the time of publication, Pharmaron (03759) rose 6.66%, Viva Biotech (01873) rose 5.05%, Tigermed (03347) rose 2.84%, and Wuxi Bio (02269) rose 2.77%. On the news side, Orient Securities stated that according to the latest data on the key indicators of the CRO industry's prosperity index, the global fund has basically stabilized, while the domestic investment and financing side is still tight; however, the enthusiasm for research and development has not diminished, and the IND and new clinical trials are still at a high level. The bank believes that the CXO sector, after experiencing double killings in performance and valuation, is expected to welcome a
No Data